Sarah G Mars1, Daniel Rosenblum2, Daniel Ciccarone1. 1. Department of Family and Community Medicine, University of California San Francisco, CA, USA. 2. Department of Economics, Dalhousie University, Halifax, NS, Canada.
Abstract
BACKGROUND: Illicitly manufactured fentanyl and its analogues are appearing in countries throughout the world, often disguised as heroin or counterfeit prescription pills, with resulting high overdose mortality. Possible explanations for this phenomenon include reduced costs and risks to heroin suppliers, heroin shortages, user preferences for a strong, fast-acting opioid and the emergence of Dark Web cryptomarkets. This paper addresses these potential causes and asks three questions: (1) can users identify fentanyl; (2) do users desire fentanyl; and (3) if users want fentanyl, can they express this demand in a way that influences the supply? ARGUMENT/ANALYSIS: Existing evidence, while limited, suggests that some users can identify fentanyl, although not reliably, and some desire it, but because fentanyl is frequently marketed deceptively as other drugs, users lack information and choice to express demand effectively. Even when aware of fentanyl's presence, drug users may lack fentanyl-free alternatives. Cryptomarkets, while difficult to quantify, appear to offer buyers greater information and competition than offline markets. However, access barriers and patterns of fentanyl-related health consequences make cryptomarkets unlikely sources of user influence on the fentanyl supply. Market condition data indicate heroin supply shocks and shortages prior to the introduction of fentanyl in the United States and parts of Europe, but the much lower production cost of fentanyl compared with heroin may be a more significant factor CONCLUSION: Current evidence points to a supply-led addition of fentanyl to the drug market in response to heroin supply shocks and shortages, changing prescription opioid availability and/or reduced costs and risks to suppliers. Current drug users in affected regions of the United States, Canada and Europe appear largely to lack both concrete knowledge of fentanyl's presence in the drugs they buy and access to fentanyl-free alternatives.
BACKGROUND: Illicitly manufactured fentanyl and its analogues are appearing in countries throughout the world, often disguised as heroin or counterfeit prescription pills, with resulting high overdosemortality. Possible explanations for this phenomenon include reduced costs and risks to heroin suppliers, heroin shortages, user preferences for a strong, fast-acting opioid and the emergence of Dark Web cryptomarkets. This paper addresses these potential causes and asks three questions: (1) can users identify fentanyl; (2) do users desire fentanyl; and (3) if users want fentanyl, can they express this demand in a way that influences the supply? ARGUMENT/ANALYSIS: Existing evidence, while limited, suggests that some users can identify fentanyl, although not reliably, and some desire it, but because fentanyl is frequently marketed deceptively as other drugs, users lack information and choice to express demand effectively. Even when aware of fentanyl's presence, drug users may lack fentanyl-free alternatives. Cryptomarkets, while difficult to quantify, appear to offer buyers greater information and competition than offline markets. However, access barriers and patterns of fentanyl-related health consequences make cryptomarkets unlikely sources of user influence on the fentanyl supply. Market condition data indicate heroin supply shocks and shortages prior to the introduction of fentanyl in the United States and parts of Europe, but the much lower production cost of fentanyl compared with heroin may be a more significant factor CONCLUSION: Current evidence points to a supply-led addition of fentanyl to the drug market in response to heroin supply shocks and shortages, changing prescription opioid availability and/or reduced costs and risks to suppliers. Current drug users in affected regions of the United States, Canada and Europe appear largely to lack both concrete knowledge of fentanyl's presence in the drugs they buy and access to fentanyl-free alternatives.
Authors: Irfan A Dhalla; Muhammad M Mamdani; Marco L A Sivilotti; Alex Kopp; Omar Qureshi; David N Juurlink Journal: CMAJ Date: 2009-12-07 Impact factor: 8.262
Authors: Nicholas Baldwin; Roger Gray; Anirudh Goel; Evan Wood; Jane A Buxton; Launette Marie Rieb Journal: Drug Alcohol Depend Date: 2018-02-20 Impact factor: 4.492
Authors: Nicholas J Somerville; Julie O'Donnell; R Matthew Gladden; Jon E Zibbell; Traci C Green; Morgan Younkin; Sarah Ruiz; Hermik Babakhanlou-Chase; Miranda Chan; Barry P Callis; Janet Kuramoto-Crawford; Henry M Nields; Alexander Y Walley Journal: MMWR Morb Mortal Wkly Rep Date: 2017-04-14 Impact factor: 17.586
Authors: Maxwell S Krieger; Jesse L Yedinak; Jane A Buxton; Mark Lysyshyn; Edward Bernstein; Josiah D Rich; Traci C Green; Scott E Hadland; Brandon D L Marshall Journal: Harm Reduct J Date: 2018-02-08
Authors: Rebekah D Tenney; Steven Blake; Paul T Bremer; Bin Zhou; Candy S Hwang; Justin L Poklis; Kim D Janda; Matthew L Banks Journal: Neuropharmacology Date: 2019-07-29 Impact factor: 5.250
Authors: Alyona Mazhnaya; Allison O'Rourke; Rebecca Hamilton White; Ju Nyeong Park; Michael E Kilkenny; Susan G Sherman; Sean T Allen Journal: Subst Use Misuse Date: 2020-05-22 Impact factor: 2.164
Authors: A Salomone; R Bigiarini; J J Palamar; C McKnight; L Vinsick; E Amante; D Di Corcia; M Vincenti Journal: J Anal Toxicol Date: 2020-05-18 Impact factor: 3.367
Authors: Andrea Meier; Sarah K Moore; Elizabeth C Saunders; Bethany McLeman; Stephen A Metcalf; Samantha Auty; Olivia Walsh; Lisa A Marsch Journal: Drug Alcohol Depend Date: 2020-02-07 Impact factor: 4.492
Authors: Ricky N Bluthenthal; Kelsey Simpson; Rachel Carmen Ceasar; Johnathan Zhao; Lynn Wenger; Alex H Kral Journal: Drug Alcohol Depend Date: 2020-03-18 Impact factor: 4.492